Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury

• FARRELL GC: Drug-induced acute hepatitis. In: Drug-induced Liver Disease. Farrell GC (Ed.), Churchill Livingstone, Edinburgh, UK (1994):262-272.
   Google Scholar
• GARG PK, TANDON RK: Antituberculosis agents-induced liver injury. In: Drug-induced Liver Disease. Kaplowitz N, Deleve LD (Eds), Marcel Dekker, New York, USA (2003):505-517.
   Google Scholar
• ROY B: Anti-tuberculosis drug induced hepatotoxicity and genetic polymorphisms in drug-metabolizing genes. Curr. Pharmacogenomics (2003) 1(2):101-109.
   Google Scholar
• OHNO M, YAMAGUCHI I, YAMAMOTO I etal.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung D. (2000) 4(3):257-261.
   Google Scholar
• HUANG YS, CHERN HD, SU WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of antituberculosis drug-induced hepatitis. Hepatology (2002) 35(4):883-889.
   PubMed Web of Science ®Google Scholar
• HUANG YS, CHERN HD, SU WJ et al.: Cytochrome P450 2E1 genetic polymorphism and the susceptibility to anti-tuberculosis drug-induced hepatitis. Hepatology (2003) 37(4):924-930.
   PubMed Web of Science ®Google Scholar
• BLACK M, MITCHELL JR, ZIMMERMAN HJ, ISHAK KG, EPLER GR: Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 69(2):289-302.
   PubMed Web of Science ®Google Scholar
• MITCHELL JR, THORGEIRSSON UP, BLACK M etal.: Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin. Pharmacol. Ther. (1975) 18(1):70-79.
   Google Scholar
• MITCHELL JR, ZIMMERMAN HJ, ISHAK KG et al.: Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann. Intern. Med. (1976) 84(2):181-192.
   Google Scholar
• KOPANOFF DE, SNIDER DE, CARAS GJ: Isoniazid-related hepatitis: a US public health service cooperative surveillance study. Am. Rev. Respir. Dis. (1978) 117(6):991-1001.
   Google Scholar
• GRÖNHAGEN-RISKA C, HELLSTROM PE, FRÖSETH B: Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am. Rev. Respir. Dis. (1978) 118(3):461-466.
   Google Scholar
• BYRD CRB, HORN BR, SOLOMON DA, GRIGGS GA: Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1000 patients. J. Am. Med. Assoc. (1979) 241(12):1239-1241.
   Google Scholar
• DICKINSON DS, BAILEY WC, HIRSCHOWITZ BI, SOONG SJ, EIDUS L, HIDGKIN MM: Risk factors for isoniazid (INH)-induced liver dysfunction. J. Clin. Gastroenterol. (1981) 3(3):271-279.
   Google Scholar
• MADDREY WC: Isoniazid-induced liver disease. Semin. Liver. Dis. (1981) 1(2):129-133.
   PubMedGoogle Scholar
• GURUMURTHY P, KRISHNAMURTHY MS, NAZARETH O et al.: Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am. Rev. Respir. Dis. (1984) 129(1):58-61.
   Google Scholar
• YAMATOTO T, SUOU T, HIRAYAMA C: Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology (1986) 6(2):295-298.
   PubMed Web of Science ®Google Scholar
• SARMA GR, IMMANUEL C, KAILASAM S, NARAYANA AS, VENKATESAN P: Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am. Rev. Respir. Dis. (1986) 133(6):1072-1075.
   Google Scholar
• PARTHASARATHY R, SARMA GR, JANARDHANAM B et al.: Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle. (1986) 67(2):99-108.
   PubMedGoogle Scholar
• WU JC, LEE SD, YEH PF et al.: Isoniazid–rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology (1990) 98(2):502-504.
   PubMed Web of Science ®Google Scholar
• PARRISH AG, ROBSON SC, TREY C, KIRSCH RE: Retrospective survey of drug-induced liver disease at Groot Schuur Hospital, Cape Town – 1983 – 1987. S. Afr. Med. J. (1990) 77(4):199-202.
   Google Scholar
• SINGH J, GARG PK, THAKUR VS, TANDON RK. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J. Physiol. Pharmacol. (1995) 39(1):43-46.
   PubMedGoogle Scholar
• PANDE JN, SINGH SPN, KHILNANI GC, KHILNANI S, TANDON RK: Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax (1996) 51(2):132-136.
   PubMed Web of Science ®Google Scholar
• WONG WM, WU PC, YUEN MF et al.: Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatolology (2000) 31(1):201-206.
   PubMed Web of Science ®Google Scholar
• ACHARYA SK, DASARATHY S, KUMER TL et al.: Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology (1996) 23(6):1448-1455.
   PubMed Web of Science ®Google Scholar
• DURAND F, BERNUAU J, PESSAYRE D etal.: Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology (1995) 21(4):929-932.
   PubMed Web of Science ®Google Scholar
• JASMER RM, SAUKKONEN JJ, BLUMBERG HM etal.: Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann. Intern. Med. (2002) 137(8):640-647.
   PubMed Web of Science ®Google Scholar
• ROY B, CHOWDHURY A, KUNDU S et al.: Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J. Gastroenterol. Hepatol. (2001) 16(9):1033-1037.
   Google Scholar
• ROY B, GHOSH SK, SUTRADHAR D etal.: Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J. Gastroenterol. Hepatol. (2006) 21(4):784-786.
   PubMed Web of Science ®Google Scholar
• VUILLEUMIER N, ROSSIER MF, CHIAPPE A etal.: CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. (2006) 62(6):423-429.
   PubMedGoogle Scholar
• RYAN DE, RAMANATHAN L, IIDA S et al.: Characterization of a major form of rat hepatic microsomal cytochrome P450 induced by isoniazid. J. Biol. Chem. (1985) 260(10):6385-6393.
   Google Scholar
• LAUTERBURG BH, SMITH CV, TODD EL, MITCHELL JR: Pharmacokinetics of the toxic hydrazine metabolites formed from isoniazid in humans. J. Pharmacol. Exp. Ther. (1985) 235(3):566-570.
   Google Scholar
• ELLARD GA, GAMMON PT: Pharmacokinetics of isoniazid metabolism in man. J. Pharmacokinet. Biop. (1976) 4(2):83-113.
   Google Scholar
• ROTHMAN N, HAYES RB, BI W et al.: Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics (1993) 3(5):250-255.
   PubMedGoogle Scholar
• ZIELINSKA E, NIEWIAROWSKI W, BODALSKI J et al.: Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim–sulfamethoxazole in infants. Pharm. World. Sci. (1998) 20(3):123-130.
   Google Scholar
• BELL DA, TAYLOR JA, BUTLER MA et al.: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis (1993) 14(8):1689-1692.
   PubMed Web of Science ®Google Scholar
• HEIN DW, DOLL MA, RUSTAN TD, FERGUSON RJ: Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. (1995) 55(16):3531-3536.
   PubMed Web of Science ®Google Scholar
• LIN HJ, HAN CY, LIN BK, HARDY S: Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics (1994) 4(3):125-134.
   PubMedGoogle Scholar
• TIMBRELL JA, WRIGHT JM, BAILLIE TA: Monoacetylhydrazine as a metabolite of isoniazid in man. Clin. Pharmacol. Ther. (1977) 22(5 Pt 1):602-608.
   Google Scholar
• GUENGERICH FP, SHIMADA T: Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res. (1998) 400(1-2):201-213.
   Google Scholar
• TSUTSUMI M, TAKADA A, WANG JS: Genetic polymorphism of cytochrome P450 2E1 related to the development of alcoholic liver disease. Gastroenterology (1994) 107(5):1430-1435.
   PubMed Web of Science ®Google Scholar
• YU MW, GLADEK-YARBOROUGH A, CHIAMPRASERT S, SANTELLA RM, LIAW YF, CHEN CJ: Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology (1995) 109(4):1266-1273.
   PubMed Web of Science ®Google Scholar
• WATKINS PB: The role of cytochrome P450s in drug-induced liver disease. In: Drug-induced Liver Disease. Kaplowitz N, Deleve LD (Eds), Marcel Dekker, New York, USA (2003):15-33.
   Google Scholar
• WATANABE J, HAYASHI S, KAWAJIRI K: Different regulations and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′ flanking region. J. Biochem. (1994) 116(2):321-326.
   Google Scholar
• HAYASHI S, WATANABE J, KAWAJIRI K: Genetic polymorphism in the 5′-flanking region change transcriptional regulation of the human cytochrome P450 II E1 gene. J. Biochem. (1991) 110(4):559-565.
   Google Scholar
• STEPHENS EA, TAYLOR JA, KAPLAN N et al.: Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics (1994) 4(4):185-192.
   PubMedGoogle Scholar
• LUCAS D, MÉNEZ C, GIRRE C et al.: Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics (1995) 5(5):298-304.
   PubMedGoogle Scholar
• POWELL H, KITTERINGHAM NR, PIRMOHAMED M, SMITH DA, PARK BK: Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics (1998) 8(5):411-421.
   PubMedGoogle Scholar
• ZAND R, NELSON SD, SLATTERY JT et al.: Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin. Pharmacol. Ther. (1993) 54(2):142-149.
   Google Scholar
• SARICH TC, ADAMS SP, PETRICCA G, WRIGHT JM: Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J. Pharmacol. Exp. Ther. (1999) 289(2):695-702.
   Google Scholar
• DESTA Z, SOUKHOVA NV, FLOCKHART DA: Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents. Ch. (2001) 45(2):382-392.
   Web of Science ®Google Scholar
• PARK KS, SOHN DH, VEECH RL, SONG BJ: Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid. Eur. J. Pharmacol. (1993) 248(1):7-14.
   Google Scholar
• STRANGE RC, JONES PW, FRYER AA: Glutathione S-transferase: genetics and role in toxicology. Toxicol. lett. (2000) 112-113:357-363.
   PubMed Web of Science ®Google Scholar
• SIMON T, BECQUEMONT L, MARYPKRAUSE M et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. (2000) 67(4):432-437.
   PubMed Web of Science ®Google Scholar
• WATANABE I, TOMITA A, SHIMIZU M et al.: A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. (2003) 73(5):435-455.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BALAMURUGAN A, SAHA PK, PANDEY RM, MEHRA K: Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Resp. Crit. Care (2002) 166(7):916-919.
   PubMed Web of Science ®Google Scholar

Website

• http://www.cypalleles.ki.se/cyp2e1.htmThe Institute of Environmental Medicine, Karolinska Institute websites (2006).
   Google Scholar